ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine hydrochloride; riboflavin 5'-phosphate sodium; thiamine hydrochloride; vitamin a; vitamin e
Drug data last refreshed 6d ago · AI intelligence enriched 2w ago
M.V.C. 9+3 is a multi-vitamin injectable formulation containing 12 essential vitamins (A, B-complex, C, D, E) used to treat or prevent vitamin deficiencies in patients unable to take oral supplements. The product addresses nutritional gaps in hospitalized, critically ill, or malnourished populations requiring parenteral nutrition support.
As a mature injectable vitamin formulation approaching LOE, the product likely operates with a lean, cost-focused team in late-stage brand management and hospital distribution roles.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on M.V.C. 9+3 typically positions you in operational and support-level roles within established pharmaceutical infrastructure, with limited exposure to cutting-edge drug development or commercial launch activities. Career growth relies on internal mobility into adjacent therapeutic areas or transition to hospital/institutional sales and compliance functions.
Worked on M.V.C. 9+3 at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
2 open roles linked to this drug